- £102.79m
- £146.69m
- £247.10m
- 94
- 90
- 98
- 100
C2019 March 31st | 2020 March 31st | R2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 200 | 189 | 165 | 195 | 247 |
Cost of Revenue | |||||
Gross Profit | 129 | 121 | 105 | 130 | 162 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 184 | 179 | 155 | 179 | 224 |
Operating Profit | 15.4 | 10.1 | 10.7 | 16.2 | 22.9 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 10.4 | 4.9 | 6.1 | 12.4 | 17.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | 6.9 | 3.4 | 4.6 | 10.2 | 11.8 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 6.5 | 1.8 | 4.6 | 10.2 | 11.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 6.5 | 1.8 | 4.6 | 10.2 | 11.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.027 | 0.026 | 0.007 | 0.045 | 0.06 |